Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis

This study is for patients with IPF (Idiopathic Pulmonary Fibrosis) to see how well a new medication works with current standard treatment on lung function and IPF disease in general.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03711162
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 40 or greater
Diagnosis of Idiiopathic Pulmonary Fibrosis (IPF) within the past 5 years
Exclusion Criteria:
HIV or hepatitis B or C diagnosis
History of malignancy within the past 5 years
Acute IPF reoccurrence in the past 6 months
Lower respiratory tract infection in the past 4 weeks requiring antibiotics
History of lung volume reduction surgery or lung transplant
Lung Disease & Asthma
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA